- New Data Presented at the 10th Annual Heart Rhythm Congress - SAN DIEGO, CA., October 6, 2015— Acutus Medical, a global heart rhythm technology company, today presented data that demonstrated the ability of the AcQMap™ High Resolution Imaging and Mapping System to precisely overlay highresolution
Data Presented at Heart Rhythm Society’s 36th Annual Scientific Sessions -SAN DIEGO, CA. May 15, 2015 – Acutus Medical, Inc., an innovative medical device company committed to revolutionizing the diagnosis and treatment of irregular and complex heart rhythm disorders, today presented data that
SAN DIEGO, CA. April 30, 2014 —Acutus Medical announces the receipt of the CE Mark for its proprietary real-time 3D diagnostic imaging and dipole density mapping catheter. “The Katheter” is one part of the new stand-alone system being developed by Acutus Medical.
GE Ventures and OrbiMed join Index and Advent in the funding of Acutus Medical’s Novel Dipole Density Electrophysiology Mapping System, Generating CT/MRI Quality, Real-Time 3D Images of the Heart Chamber & Electrical Conduction San Diego, CA – August 20, 2013 – Acutus Medical, Inc.
SAN DIEGO, June 25, 2013 /PRNewswire/ — Acutus Medical, Inc. (ACM), a medical device company developing a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system for the identification of the sources that cause and/or sustain complex cardiac arrhythmias, including
San Diego, California, April 30, 2013—Acutus Medical, Inc. (ACM or Company), an emerging developer and manufacturer of medical devices designed to provide real-time 3D cardiac electrical mapping based on dipole density for the treatment of cardiac arrhythmias, announced today that it has performed
SAN DIEGO, look CA.—Acutus Medical announced the issuance of U.S. Patent number 8, click 417, 313 which relates to the method and device for determining and presenting surface charge and dipole density on cardiac walls. This patent focuses on an innovative method in cardiac electrophysiology
Three years ago, malady the FDA approved Johnson & Johnson’s thermocool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to
—Funds and team growth for developing a breakthrough medical system for mapping of atrial fibrillation— 20th January 2012, London: – Advent Life Sciences announced it has invested $2.2 million in Acutus Medical, a medical technology company based in San Diego and Zurich, as part of a Series A of
New medical technology company focused on developing a breakthrough device for real time mapping of Atrial Fibrillation 8th August 2011, San Diego, USA: – Index Ventures, together with private investors, has invested an initial funding of $1 million in Acutus Medical, a newly founded medical